CD274 and gastric cancer: Based on these results it is difficult to see a role for bevacizumab in OG cancer at present, although there are currently phase 1 trials investigating bevacizumab in combination with the anti PDL-1 monocolonal antibody atezolizumab in solid tumors, including esophageal, and gastric cancers (NCT02715531, NCT01633970).